Johnson & Johnson Stock Forecast for 2022 - 2025 - 2030

Updated on 10/01/2022

Stock Rating
12
Price Target
$182.00
Consensus
Outperform
Upside
10.62%
Analysts
3
Stock Rating
12
Upside
10.62%
Analysts
3
Price Target
$182.00

Johnson & Johnson Stock Forecast and Price Target

Johnson & Johnson's most recent price target of $182.00 for 2022 was provided by three renowned analysts over the past few months, with an average prediction of $182.00. If this prediction is correct, Johnson & Johnson's stock could rise by 10.62 percent from its current trading price. The potential increase for the stock is $182.00 per share, with a possible range of $164.00 to $215.00. Even if you are not interested in JNJ stock, you should still be aware of its competitors.

$182.00

10.62% Upside

Outperform
Outperform

Johnson & Johnson Fair Value Forecast for 2022 - 2025 - 2030

Johnson & Johnson's Price has grown in the last four years, jumping from $128.63 to $172.68 – an increase of 34.25%. In the next year, analysts predict that Fair Value will reach $180.78 – an increase of 4.69%. For the next nine years, the forecast is for Fair Value to grow by 32.65%.

2022 Fair Value Forecast
$180.78
2023 Fair Value Forecast
$192.41
2024 Fair Value Forecast
$201.22
2025 Fair Value Forecast
$212.85
2026 Fair Value Forecast
$209.68
2027 Fair Value Forecast
$209.33
2028 Fair Value Forecast
$215.32
2029 Fair Value Forecast
$219.19
2030 Fair Value Forecast
$229.06
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ABBV Stock Forecast AbbVie Outperform 9
$142.72 Buy/Sell $164.23 9.30%
ABT Stock Forecast Abbott Laboratories Outperform 14
$98.29 Buy/Sell $128.88 27.68%
AZN Stock Forecast AstraZeneca PLC Outperform 18
£99.33 Buy/Sell £136.08 41.24%
BMY Stock Forecast Bristol-Myers Squibb Outperform 2
$71.71 Buy/Sell $79.05 15.74%
AMGN Stock Forecast Amgen Hold 9
$228.41 Buy/Sell $246.51 11.64%

Johnson & Johnson Revenue Forecast for 2022 - 2025 - 2030

Johnson & Johnson's Revenue has grown in the last four years, jumping from $76.45B to $93.78B – an increase of 22.66%. In the next year, analysts predict that Revenue will reach $96.30B – an increase of 2.69%. For the next nine years, the forecast is for Revenue to grow by 12.28%.

2022 Rev Forecast
$96.30B
2023 Rev Forecast
$100.28B
2024 Rev Forecast
$103.17B
2025 Rev Forecast
$106.86B
2026 Rev Forecast
$105.05B
2027 Rev Forecast
$105.72B
2028 Rev Forecast
$103.67B
2029 Rev Forecast
$103.65B
2030 Rev Forecast
$105.29B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BDX Stock Forecast Becton, Dickinson and Outperform 17
$226.12 Buy/Sell $278.08 23.83%
MMM Stock Forecast 3M Hold 16
$112.30 Buy/Sell $147.79 21.99%
BSX Stock Forecast Boston Scientific Buy 15
$39.34 Buy/Sell $49.85 22.01%

Johnson & Johnson Dividend per Share Forecast for 2022 - 2025 - 2030

In the last four years, Johnson & Johnson's Dividend per Share has increased by 26.20%, going from $3.32 to $4.19. In the next year, analysts are expecting an increase in Dividend per Share, predicting it will reach $4.45 – an increase of 6.21%. The Johnson & Johnson forecast is for Dividend per Share to reach $5.75 or grow by 37.23%.

2022 DPS Forecast
$4.45
2023 DPS Forecast
$4.63
2024 DPS Forecast
$4.85
2025 DPS Forecast
$5.15
2026 DPS Forecast
$5.27
2027 DPS Forecast
$5.34
2028 DPS Forecast
$5.41
2029 DPS Forecast
$5.51
2030 DPS Forecast
$5.75
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BAYN Stock Forecast Bayer Outperform 7
47.72€ Buy/Sell 67.79€ 66.60%
4519 Stock Forecast Chugai Pharmaceutical Hold 18
¥3.63k Buy/Sell ¥0.00 23.97%
BIIB Stock Forecast Biogen Outperform 11
$264.28 Buy/Sell $242.78 2.16%

Johnson & Johnson Free Cash Flow Forecast for 2022 - 2025 - 2030

Johnson & Johnson's Free Cash Flow has increased by 11.14% In the last four years, going from $17.78B to $19.76B. In the next year, analysts expect Free Cash Flow to reach $23.17B – an increase of 17.29%. For the next nine years, the forecast is for Free Cash Flow to grow by 47.66%.

2022 FCF Forecast
$23.17B
2023 FCF Forecast
$26.97B
2024 FCF Forecast
$28.05B
2025 FCF Forecast
$26.74B
2026 FCF Forecast
$26.55B
2027 FCF Forecast
$26.03B
2028 FCF Forecast
$25.74B
2029 FCF Forecast
$28.81B
2030 FCF Forecast
$29.17B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BAS Stock Forecast BASF Outperform 11
38.85€ Buy/Sell 78.27€ 41.57%
BNTX Stock Forecast BioNTech Outperform 12
$133.60 Buy/Sell $0.00 50.00%
BAX Stock Forecast Baxter International Outperform 17
$55.30 Buy/Sell $69.92 24.77%

Johnson & Johnson Net Income Forecast for 2022 - 2025 - 2030

In the last four years, Johnson & Johnson's Net Income has grown, increasing from $1.30B to $20.88B – an increase of 1506.00%. For next year, the 17 analysts predict Net Income of $27.22B, which would mean an increase of 30.39%. Over the next nine years, the pros' prediction is Net Incomeof $29.27B, which would mean a nine-year growth forecast of 40.20%.

2022 NI Forecast
$27.22B
2023 NI Forecast
$28.77B
2024 NI Forecast
$29.94B
2025 NI Forecast
$31.14B
2026 NI Forecast
$30.18B
2027 NI Forecast
$29.48B
2028 NI Forecast
$28.65B
2029 NI Forecast
$28.58B
2030 NI Forecast
$29.27B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ALC Stock Forecast Alcon Outperform 15
CHF55.44 Buy/Sell CHF0.00 52.71%
BEI Stock Forecast Beiersdorf Outperform 17
100.20€ Buy/Sell 102.71€ 11.78%
CHD Stock Forecast Church & Dwight Hold 11
$72.92 Buy/Sell $90.41 22.19%

Johnson & Johnson EBITDA Forecast for 2022 - 2025 - 2030

In the last four years, Johnson & Johnson's EBITDA has grown, increasing from $24.54B to $32.64B – a growth of 33.00%. The next year looks promising for Johnson & Johnson, with analysts predicting EBITDA of $34.27B – an increase of 5.02%. Over the next nine years, experts anticipate that Johnson & Johnson's EBITDA will grow at a rate of 66.01%.

2022 EBITDA Forecast
$34.27B
2023 EBITDA Forecast
$36.70B
2024 EBITDA Forecast
$38.51B
2025 EBITDA Forecast
$41.20B
2026 EBITDA Forecast
$43.65B
2027 EBITDA Forecast
$46.09B
2028 EBITDA Forecast
$48.77B
2029 EBITDA Forecast
$51.44B
2030 EBITDA Forecast
$54.18B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BGNE Stock Forecast BeiGene Outperform 6
$136.28 Buy/Sell $0.00 120.14%
AKZA Stock Forecast Akzo Nobel N.V. Outperform 18
56.80€ Buy/Sell 113.10€ 91.02%
AFX Stock Forecast Carl Zeiss Meditec Outperform 18
103.15€ Buy/Sell 165.40€ 44.45%

Johnson & Johnson EBIT Forecast for 2022 - 2025 - 2030

In the last four years, Johnson & Johnson's EBIT has grown by 33.60%, from $18.90B to $25.25B. For the next year, analysts are expecting EBIT to reach $30.91B – an increase of 22.45%. Over the next nine years, experts predict that EBIT will grow by 39.26%.

2022 EBIT Forecast
$30.91B
2023 EBIT Forecast
$33.15B
2024 EBIT Forecast
$34.55B
2025 EBIT Forecast
$34.38B
2026 EBIT Forecast
$34.46B
2027 EBIT Forecast
$34.67B
2028 EBIT Forecast
$34.83B
2029 EBIT Forecast
$34.98B
2030 EBIT Forecast
$35.16B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BBWI Stock Forecast Bath & Body Works Outperform 15
$33.63 Buy/Sell $52.00 42.73%
CLN Stock Forecast Clariant Hold 18
CHF14.85 Buy/Sell CHF19.93 31.99%
7747 Stock Forecast Asahi Intecc Outperform 16
¥2.33k Buy/Sell ¥0.00 29.03%

Johnson & Johnson EPS Price Prediction Forecast for 2022 - 2025 - 2030

Johnson & Johnson's EPS has grown in the last four years, jumping from $7.30 to $9.80 – an increase of 34.25%. In the next year, analysts predict that EPS will reach $10.26 – an increase of 4.69%. For the next nine years, the forecast is for EPS to grow by 32.65%.

2022 EPS Forecast
$10.26
2023 EPS Forecast
$10.92
2024 EPS Forecast
$11.42
2025 EPS Forecast
$12.08
2026 EPS Forecast
$11.90
2027 EPS Forecast
$11.88
2028 EPS Forecast
$12.22
2029 EPS Forecast
$12.44
2030 EPS Forecast
$13.00
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CCXI Stock Forecast ChemoCentryx Outperform 8
$51.66 Buy/Sell $34.75 24.85%
ALKS Stock Forecast Alkermes Hold 10
$22.46 Buy/Sell $0.00 42.48%
AUROPHARMA Stock Forecast Aurobindo Pharma Outperform 18
Rp509.70 Buy/Sell Rp946.91 56.96%